Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05815199

E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness

Effectiveness and Impact of Counseling Enhanced Using Electronic Cigarettes for Harm Reduction in People With Serious Mental Illness

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
NYU Langone Health · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

In this open-label, randomized controlled trial study, participants who smoke combustible cigarettes (CC) and are diagnosed with Serious Mental Illness (SMI) will be randomized in two arms to receive harm-reduction counseling and Ecological Momentary Intervention text messaging (EMI) along with either e-cigarettes (EC) or nicotine replacement therapy (NRT) such as patch and lozenges to compare the efficacy in CC smoking reduction.

Conditions

Interventions

TypeNameDescription
OTHERE-cigarette (EC)Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
OTHERNicotine Replacement Therapy (NRT)Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
BEHAVIORALHarm-Reduction CounselingAt baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
BEHAVIORALEcological Momentary Intervention (EMI) Text MessagingEMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.

Timeline

Start date
2023-11-13
Primary completion
2026-03-01
Completion
2026-03-01
First posted
2023-04-18
Last updated
2025-10-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05815199. Inclusion in this directory is not an endorsement.